News
PFGTF
0.099
NaN%
--
Pacific Edge Appoints Simon Richard Flood as Independent Director
TipRanks · 12/08 02:48
Pacific Edge Limited Announces Director’s Interest Disclosure
TipRanks · 12/04 02:09
Pacific Edge Appoints Simon Flood as Chairman Designate
TipRanks · 12/03 20:47
Pacific Edge Earnings Call: Mixed Sentiments and Strategic Moves
TipRanks · 11/27 00:07
Pacific Edge Appoints New CCO to Boost Cxbladder Adoption
TipRanks · 11/26 20:49
Pacific Edge Limited Reports Earnings Amid Medicare Challenges
TipRanks · 11/25 03:53
Pacific Edge Positions for Medicare-Led Recovery Amid Revenue Decline
TipRanks · 11/24 21:02
Pacific Edge Limited Announces Lapse of Share Options
Barchart · 10/14 22:10
Pacific Edge Limited Seeks ASX Quotation for New Securities
Barchart · 10/14 21:54
Pacific Edge Limited Announces Cessation of Securities
Barchart · 10/14 21:38
Pacific Edge Faces Challenges with Cxbladder Test Volumes Amid Medicare Coverage Loss
Barchart · 10/14 15:46
Weekly Report: what happened at PFGTF last week (0908-0912)?
Weekly Report · 09/15 09:30
Pacific Edge Welcomes Novitas’ Expert Panel on AUA Guideline
TipRanks · 09/14 21:49
Weekly Report: what happened at PFGTF last week (0901-0905)?
Weekly Report · 09/08 09:31
Weekly Report: what happened at PFGTF last week (0825-0829)?
Weekly Report · 09/01 09:29
Pacific Edge Limited Faces Compliance Inquiry Amid Stock Surge
TipRanks · 08/26 02:27
More
Webull provides a variety of real-time PFGTF stock news. You can receive the latest news about Pacific Edge Ltd through multiple platforms. This information may help you make smarter investment decisions.
About PFGTF
Pacific Edge Limited is a global cancer diagnostics company. The Company is engaged in the development and commercialization of bladder cancer diagnostic and prognostic tests for patients presenting with hematuria or surveillance of recurrent disease. The Company operates through two segments: Commercial and Research. The Commercial segment is engaged in the sales, marketing, laboratory, and support operations to run the commercial businesses worldwide. The Research segment is engaged in the research and development of diagnostic and prognostic products for human cancer. The Company provides its suite of Cxbladder tests globally through its wholly owned laboratories in New Zealand and the United States. Its Cxbladder tests assist clinicians to safely de-intensify hematuria evaluation from low incidence populations; resolve diagnostic dilemmas and monitor patients for the recurrence of urothelial carcinoma. It operates in New Zealand, Australia, Singapore, and the United States.